Eli Lilly and Co, Novo-Nordisk A/S, and Amgen will announce key results from their weight loss drug trials during the upcoming American Diabetes Association annual meeting.
According to Zhituo Finance APP, weight loss drug giants Eli Lilly and Co (LLY.US), Novo-Nordisk A/S (NVO.US), and Amgen (AMGN.US) plan to announce the results of their major clinical trials at the 85th Scientific Sessions of the American Diabetes Association (ADA) to be held in Chicago from June 20 to 23.
Eli Lilly will present the results of its Phase 3 clinical trial for the oral weight loss therapy (orforglipron) targeting adult patients with type 2 diabetes at a seminar hosted by the ADA on June 21. The pharmaceutical company announced the final data of the ACHIEVE-1 trial in April, indicating that this global trial (the first of seven Phase 3 clinical trials for orforglipron) achieved its primary goal, with patients experiencing an average weight loss of about 8% over the 40-week trial period.
Novo-Nordisk A/S will also participate in the seminar on June 22 to announce data from its next-generation weight loss therapy CagriSema's REDEFINE 1 and REDEFINE 2 Phase 3 clinical trials. The Danish pharmaceutical company's stocks plummeted in December due to the failure of this weekly injection drug to meet initial expectations in its REDEFINE 1 Phase 3 trial. The trial's participants were adults suffering from obesity or overweight with one or more related conditions.
The company stated before the event: "The presentation of CagriSema REDEFINE 1 and 2 trial data is the first time that Phase 3 clinical data regarding the combination of GLP-1 and amylin receptor agonists has been released, providing important insights into the potential of this candidate drug."
Meanwhile, the safety of Amgen's experimental weight loss therapy MariTide will be a focal point. The company will announce the full data from a Phase 2 clinical trial of this injectable on June 23.
Amgen's stocks dropped in November because the company reported that MariTide resulted in an average weight loss of up to 20% for subjects in a 52-week trial. The trial recruited individuals with obesity or overweight who did not have type 2 diabetes.
Previously, a report from Cantor Fitzgerald indicated that the potential decline in bone mineral density may be a safety concern brought by the MariTide product. This product targets GLP-1 and glucose-dependent insulinotropic polypeptide receptors.
Other well-known weight loss drug research and development companies selected for the ADA conference presentation include Altimmune (ALT.US), Metsera (MTSR.US), and Vertex Pharmaceuticals (VRTX.US).
